🇺🇸 FDA
Pipeline program

Axitinib

ICR-CTSU/2011/10033

Phase 2 small_molecule completed

Quick answer

Axitinib for Clear-cell Metastatic Renal Cell Carcinoma is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Clear-cell Metastatic Renal Cell Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials